Carcinogenesis, Vol. 23, No. 9, 1531-1536,
September 2002
© 2002 Oxford University Press
CARCINOGENESIS |
Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol
Department of Surgery and Surgical Basic Science, Graduate School of Medicine, Kyoto University, 54-Shogoin Kawahra-cho, Sakyoku Kyoto 606-8507, Japan
Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a natural product occurring in grapes and various other plants with medicinal properties associated with reduced cardiovascular disease and reduced cancer risk. To evaluate the possibility and potential mechanism(s) of which resveratrol inhibits N-nitrosomethylbenzylamine (NMBA)-induced rat esophageal tumorigenesis, 96 F344 male rats were divided into 10 groups and resveratrol (1 and 2 mg/kg) was administered orally or intraperitoneally (i.p.). In the groups in which resveratrol was administered at 2 mg/kg (orally, for 16 weeks), 1 and 2 mg/kg (i.p., for 16 weeks) and 1 mg/kg (i.p., for 20 weeks), the number of NMBA-induced esophageal tumors per rat was significantly reduced to 78, 62, 54 and 48, respectively (P < 0.05), and the size of maximum tumors in each group with resveratrol treatment was also significantly smaller than that in NMBA alone group (P < 0.05). Although the pathological examination did not indicate significantly decreased incidence of carcinomas by administering resveratrol, the tendency of carcinogensis suppression was observed (P = 0.177). Semi-quantitative RT–PCR and ELISA analysis demonstrated that following NMBA treatment, the expression of COX-1 mRNA was strongly present in tumor tissues, while weakly present in non-tissues; the expression of COX-2 mRNA was induced in both tumor and non-tumor tissues. The production of prostaglandin E2 (PGE2) increased ~6-fold, compared with the normal esophageal mucosa. The higher expression of COX-1, the up-regulated COX-2 expression and the increased levels of PGE2 synthesis were all significantly decreased by administering resveratrol. Our study suggests that resveratrol suppressed NMBA-induced rat esophageal tumorigenesis by targeting COXs and PGE2, and therefore may be a promising natural anti-carcinogenesis agent for the prevention and treatment of human esophageal cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Kopelovich, J. R. Fay, C. C. Sigman, and J. A. Crowell The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1330 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Boocock, G. E.S. Faust, K. R. Patel, A. M. Schinas, V. A. Brown, M. P. Ducharme, T. D. Booth, J. A. Crowell, M. Perloff, A. J. Gescher, et al. Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive Agent Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1246 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. F. Trincheri, G. Nicotra, C. Follo, R. Castino, and C. Isidoro Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D Carcinogenesis, May 1, 2007; 28(5): 922 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sengottuvelan, P. Viswanathan, and N. Nalini Chemopreventive effect of trans-resveratrol - a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis Carcinogenesis, May 1, 2006; 27(5): 1038 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Walle, F. Hsieh, M. H. DeLegge, J. E. Oatis Jr., and U. K. Walle HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS Drug Metab. Dispos., December 1, 2004; 32(12): 1377 - 1382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Opipari Jr., L. Tan, A. E. Boitano, D. R. Sorenson, A. Aurora, and J. R. Liu Resveratrol-induced Autophagocytosis in Ovarian Cancer Cells Cancer Res., January 15, 2004; 64(2): 696 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Gescher and W. P. Steward Relationship between Mechanisms, Bioavailibility, and Preclinical Chemopreventive Efficacy of Resveratrol: A Conundrum Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 953 - 957. [Full Text] [PDF]
|
|
|
|
|
|
L. Y. Y. Fong, D. J. Feith, and A. E. Pegg Antizyme Overexpression in Transgenic Mice Reduces Cell Proliferation, Increases Apoptosis, and Reduces N-Nitrosomethylbenzylamine-induced Forestomach Carcinogenesis Cancer Res., July 15, 2003; 63(14): 3945 - 3954. [Abstract] [Full Text] [PDF]
|
|